This includes targeting alternative immune checkpoints (TIM3, CTLA-4, LAG-3), engineering therapies such as CAR-T or bispecific antibodies or designing oncolytic viruses to target specific HNSCC-related viruses. The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.